Table 2 Downstream targets of SALL4 in GIT cancers
From: SALL4 in gastrointestinal tract cancers: upstream and downstream regulatory mechanisms
Targets | Tumor | Function | Action | Signaling Pathways | References |
|---|---|---|---|---|---|
SOX2 | ESCC | Promotes invasion and metastasis | Unconfirmed | NOTCH pathway | Forghanifard et al. (2021) |
TGF-β1 | GC | Induces EMT | Direct | TGF-β/SMAD pathway | Zhang et al. (2018) |
HK-2 | GC | Promotes glycolysis, accelerates GC progression, leads to poor prognosis | Direct | Cell adhesion, glycolysis, gluconeogenesis, calcium signaling pathway | Shao et al. (2020) |
TRIB3 | GC | Promotes cancer progression | Unconfirmed | Wnt/β-catenin pathway | Yang et al. (2021a) |
CD44 | GC | Promotes cell proliferation, migration and invasion | Direct | ERK, STAT3 and NF-κB pathways | Yuan et al. (2016) |
VEGF | GC | Promotes angiogenesis | Direct | Unconfirmed | Abouelnazar et al. (2023a) |
Gli-1 | CRC | Promotes cell growth and tumor origination | Unconfirmed | Unconfirmed | Cheng et al. (2015b) |
Bcl-2 | CRC | Inhibits tumorigenesis | Unconfirmed | Unconfirmed | Hesari et al. (2019) |
β-Catenin | ESCC, CRC, HCC | Promotes proliferation, invasion, metastasis, correlates with liver cirrhosis and an advanced clinical stage | Unconfirmed Direct Unconfirmed | Wnt/β-catenin pathway | |
miR-146a-5p | HCC | Promotes tumor development by switching the dysfunction of T cells | Direct | Unconfirmed | Yin et al. (2019) |
PTEN | HCC | Suppresses tumor progression | Unconfirmed | PI3K/AKT pathway | Tang et al. (2022) |
OXPHOS-related genes | HCC | Increase oxygen consumption, mitochondrial membrane potential, and ATP generation | Direct | Unconfirmed | Tan et al. (2019) |
EpCAM, KRT19, CD44 | HCC | As an EMT and stem cell marker, promotes invasion and spheroid formation | Unconfirmed | EMT signaling pathway | Zeng et al. (2014) |
HDAC | HCC | Promotes proliferation | Unconfirmed | Unconfirmed | Zeng et al. (2014) |
KDM3A | HCC | May regulate the heterochromatin and cell death (needs to be verified) | Direct | Unconfirmed | Kong et al. (2021) |
FoxM1 | PDAC | Modulates metastasis efficiency | Unconfirmed | ERK1/2 phosphorylation |